Cite
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data.
MLA
Abé, Christoph, et al. “Cytarabine Dose Intensification Improves Survival in Older Patients with Secondary/High-Risk Acute Myeloid Leukemia in Matched Real-World versus Clinical Trial Data.” Leukemia & Lymphoma, vol. 65, no. 10, Oct. 2024, pp. 1493–501. EBSCOhost, https://doi.org/10.1080/10428194.2024.2363430.
APA
Abé, C., Keto, J., Lilja, M., Konradsen, M., Mesterton, J., Höglund, M., Lazarevic, V., Lehmann, S., & Juliusson, G. (2024). Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data. Leukemia & Lymphoma, 65(10), 1493–1501. https://doi.org/10.1080/10428194.2024.2363430
Chicago
Abé, Christoph, Jaana Keto, Mathias Lilja, Mie Konradsen, Johan Mesterton, Martin Höglund, Vladimir Lazarevic, Sören Lehmann, and Gunnar Juliusson. 2024. “Cytarabine Dose Intensification Improves Survival in Older Patients with Secondary/High-Risk Acute Myeloid Leukemia in Matched Real-World versus Clinical Trial Data.” Leukemia & Lymphoma 65 (10): 1493–1501. doi:10.1080/10428194.2024.2363430.